...
首页> 外文期刊>Journal of Drug Assessment >Medication adherence and graft survival among kidney transplant recipients
【24h】

Medication adherence and graft survival among kidney transplant recipients

机译:肾移植受者的药物依从性和移植物存活

获取原文
           

摘要

Background: Though medication adherence is essential for graft survival, non-adherence to immunosuppressants post kidney transplant is common (30–35%), potentially leading to poor quality of life and increased healthcare costs. Aims: The objective of this study was to examine the association between graft survival and adherence in kidney transplant recipients. Methods: This retrospective, observational cohort study used claims data from a single, large national pharmacy chain and post-transplant follow-up data from the OPTN Network database. The sample included adult deceased donor kidney transplant recipients (most recent transplant if more than one) who had: &2 pharmacy claims for any immunosuppressant &150?days apart in the 12?months after their first fill in the study period (2013–2016). Proportion of days covered (PDC) by any immunosuppressant for 12?months after first fill was calculated as a measure of adherence (defined as PDC &80%). Graft survival was defined as having a surviving graft at the end of the study period. Logistic regression was used to estimate the association between adherence and graft survival controlling for covariates (age at transplant, time since transplant, gender, race/ethnicity, copay, number of prescriptions for chronic conditions, pharmacy insurance plan, brand medication usage, digital fills, filling at a transplant specialized pharmacy, receiving financial assistance, the interaction between brand medication usage and receiving financial assistance, and the interaction between age and adherence). Results: Of the 14,703 kidney transplant recipients eligible for the study, 73% were adherent and 85% had a surviving graft (1 to 9780 post-transplant). After adjusting for covariates, the odds of having a surviving graft were higher for adherent patients than for non-adherent patients (OR?=?2.75, [1.95, 3.87]; p ?&?.001). Other notable factors associated with graft survival included having no post-index prescriptions for chronic conditions (OR?=?3.48, [2.95, 4.11]; p ?&?.001) and commercial insurance (vs. Medicare Part B) (OR = 1.35, [1.16, 1.56]; p ?&?.001). Conclusions: This analysis suggests adherent patients were more likely to have a surviving graft than those who were not adherent to immunosuppressants. As medication adherence behaviors may vary across patient populations, future studies should aim to show which patient behaviors contribute to medication adherence.
机译:背景:尽管坚持药物依存性对于移植物存活至关重要,但肾移植后不依从免疫抑制剂的情况很普遍(30%至35%),可能导致生活质量下降和医疗费用增加。目的:本研究的目的是研究肾移植受者的移植物存活率与依从性之间的关系。方法:这项回顾性观察队列研究使用了来自单个大型国家药房链的理赔数据和来自OPTN网络数据库的移植后随访数据。该样本包括已死亡的成年供体肾脏移植受者(如果有一个以上,则为最近一次移植),他们在以下情况下在首次填写研究期后的12个月内:≥2个药房声称任何免疫抑制剂的间隔时间≥150天。 –2016)。计算首次填充后12个月内任何免疫抑制剂覆盖的天数(PDC)的比例作为依从性的量度(定义为PDC≥80%)。移植物存活定义为在研究​​期结束时有存活的移植物。使用Logistic回归估计协变量(移植年龄,移植后时间,性别,种族/民族,共付额,慢性病处方数量,药房保险计划,品牌药物使用,数字填充)的依从性和移植物存活控制之间的关联,在移植专科药房加油,获得经济援助,使用品牌药物与获得经济援助之间的相互作用以及年龄与依从性之间的相互作用)。结果:在符合条件的14703名肾脏移植受者中,有73%的患者是依从性的,有85%的患者存活了(移植后1至9780个)。校正协变量后,依从患者的存活率高于非依从性患者(OR == 2.75,[1.95,3.87]; p 。001)。与移植物存活相关的其他值得注意的因素包括没有针对慢性病的后索引处方(OR≥3.48,[2.95,4.11]; p <0.001)和商业保险(相对于Medicare B部分)(OR = 1.35,[1.16,1.56];p≤<.001)。结论:该分析表明,与不依从免疫抑制剂的患者相比,依从患者更容易存活。由于药物依从行为可能因患者群体而异,因此未来的研究应旨在表明哪些患者行为有助于药物依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号